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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
1. To assess the effectiveness and safety of prophylactic probiotics for preventing or reducing colic in infants.
2. To identify the likely effective probiotic strains for such an approach.
B A C K G R O U N D
This protocol contains some technical terms, the definitions of
which can be found in Appendix 1.
Description of the condition
Infantile colic is defined as periods of inconsolable, unexplained,
and incessant crying in a seemingly healthy infant that, quite un-
derstandably, leads to exhausted, frustrated, and concerned par-
ents seeking to comfort their child (Landgren 2011).
Colic can affect up to 10% to 30% of infants worldwide (Clifford
2002; Rosen 2007), and although the prevalence of excessive cry-
ing varies according to the definition used, it most often peaks
during the second month of life, with a prevalence of up to 12%
(Lucassen 2001; Reijneveld 2001). Traditionally, the definition of
the condition was based on the rule of three, that is, unexplained
episodes of crying for more than three hours per day for three days
per week for at least three weeks (Wessel 1954). More recently, a
new definition has been proposed, which refers to a clinical con-
dition of fussing and crying for at least one week in an otherwise
healthy infant (Hyman 2006). Rome III diagnostic criteria for
functional gastrointestinal disorders includes the following mea-
sures, in infants from birth to four months of age, for infantile
colic: paroxysms of irritability; fussing or crying that starts and
stops without obvious cause; episodes lasting three or more hours
per day and occurring at least three days per week for at least three
weeks; and no failure to thrive (Mostafa 2008). Colic is a symptom
rather than a condition or diagnosis.
In colic, flushing of the face, meteorism (excessive flatulence in the
intestinal tract with distention of the abdomen), drawing up of
the legs, and flatulence often accompany the inconsolable crying
(Savino 2010a). Symptoms typically start in the second week of
life, in both breastfed and formula-fed infants, and usually resolve
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by three months of age (Lucas 1998). Generally speaking, these
symptoms are not indicative of disease, and thus hospital admis-
sion for these infants is generally unnecessary, detrimental, and
not to be encouraged (Savino 2007a). However, about 5% of col-
icky, crying infants do have a serious, underlying medical problem
(Freedman 2009; Savino 2005; Savino 2007a), and there is evi-
dence that older children presenting with migraine are more likely
to have been babies who had suffered colic (Romanello 2013).
Therefore, all colicky infants should undergo a complete medical
assessment in order to exclude underlying medical conditions that
require investigation and treatment (Savino 2010a).
The etiopathogenesis of infantile colic remains undefined and is
most likely multifactorial. Despite the common nature of the con-
dition, there is a general paucity of strong evidence in this area.
It has been suggested that a number of behavioural factors (psy-
chological and social) and biological components (food hypersen-
sitivity or allergy, or both; gut microorganisms; dysmotility) can
contribute to its manifestation (Gupta 2007). These include the
following.
• First, the immunological model, which focuses on possible
allergens, has been suggested as a cause of colic.
◦ A key allergen is cows’ milk proteins in infant formula
or even mothers’ milk. Intact proteins from a mother’s diet can
sometimes cross over into the breast milk, provoking an allergic
response and symptoms of colic in her infant. Consequently, a
low-allergen maternal diet or hypoallergenic infant formula have
been proposed as a form of treatment (Hill 2005; Iacovou 2012;
Schach 2002). Shannon 1921 first described the possibility of a
relationship between infantile colic and allergens, and since then,
a number of studies have evaluated the possible association
between colic and food hypersensitivity (Heine 2013; Heine
2014; Hill 1995; Iacono 1991; Lothe 1982; Merras-Salmio
2013; Saps 2011).
◦ The evidence shows that about 25% of infants with
moderate or severe symptoms have cows’ milk, protein-
dependent colic (Axelsson 1986; Hill 2000; Lindberg 1999),
which improves after some days on a hypoallergenic diet
(Campbell 1989; Dupont 2010; Estep 2000; Iacono 1991;
Iacono 2005; Jakobsson 1983, Jakobsson 2000; Lothe 1989;
Savino 2001). For these infants, infantile colic could be the first
manifestation of atopic disease, and for this reason, dietetic
treatment should be one of the first therapeutic approaches
(Gupta 2007; Hall 2012; Perry 2011; Savino 2010a). Indeed,
dietary changes are particularly indicated in cases of suspected
intolerance to cows’ milk proteins (for example, in infants with a
positive family history; eczema or onset after the first month of
life; or colic associated with other gastrointestinal symptoms,
such as vomiting or diarrhoea) (Hill 1995; Hill 2005; Jakobsson
1983; Lucassen 2000; Savino 2014). Additionally, there is
growing evidence that colic is 25% more prevalent in the babies
of cigarette smokers and mothers who have used nicotine
replacement in pregnancy and breastfeeding, suggesting that
there is an intolerance of the nicotine itself (Milidou 2012),
which manifests in symptoms of colic.
• Second, some studies have identified lactose intolerance -
due to a relative lactase deficiency - as a possible causative factor
in infant colic (Canabar 2001). Carbohydrate malabsorption
leads to the colonic fermentation of sugars and an increase in the
levels of hydrogen gas (Infante 2011). The rapid production of
hydrogen in the lower bowel distends the colon, sometimes
causing pain, whereas the osmotic pressures generated by lactose
and lactic acid in the colon cause an influx of water leading to
further distension of the bowel (Canabar 2001). Although
studies evaluating the degree of hydrogen in the breath of colicky
infants have produced inconsistent results, increases in breath
hydrogen levels have been reported (Hyams 1989; Miller 1990;
Moore 1988).
• Third, there is growing evidence that the intestinal
microbiota in colicky infants differ from those in healthy
controls, since higher levels of anaerobic bacteria, such as
coliform and Escherichia coli, and a lower concentration of
Lactobacilli have been reported in infants with colic (Savino
2010a; Savino 2013b).
◦ Recent evidence also shows that the microbiota of
infants with colicky symptoms contain greater levels of aerobic
bacteria, such as Heliobacter pylori (Ali 2012), and infants
without colicky symptoms have more varied types of microbiota
(de Weerth 2013). There is accumulating evidence that babies
who are born by caesarean section have different intestinal
microbiota (Grönlund 1999), and this and other factors affect
infant gut colonisation. A recent review by Houghteling 2015
examined these factors and the mechanisms of disease that result
from disrupted colonisation.
◦ Human milk naturally contains prebiotics; they are
defined as indigestible oligosaccharides, which could selectively
enhance the proliferation of certain probiotic bacteria in the
colon, especially Bifidobacterium species (Thomas 2010). Some
studies have failed to find a protective effect of breastfeeding on
the development of colic in breastfed infants (Clifford 2002).
However, it is unclear whether these studies compared infants
who were exclusively breastfed from birth with infants who were
exclusively artificially fed from birth, so it is still not known
whether breastfeeding has some protective effect or whether
artificial feeding compromises the infant gut microbiome in
some way. Savino 2013a, however, demonstrated higher levels of
coliforms in colicky infants who were not breastfed than in those
who were breastfed or who were not colicky. Evidence also
suggests that oligosaccharide prebiotics (a mixture of galacto-
oligosaccharides and fructo-oligosaccharides) to encourage
growth of the positive bacteria in the gut may be effective
treatments for allergy and food intolerance in general
(Arslanoglu 2012), and for crying in formula-fed infants with
colic in particular (Savino 2006).
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Many studies, such asDupont 2010, Savino 2007b, Savino 2010b,
and Szajewska 2013, and a Cochrane Review, Praveen 2014, have
looked at the treatment or management of colicky symptoms
and other functional gut disorders with probiotics and prebiotics.
However, in these times of large-scale deviation from the biolog-
ical norms of vaginal birth (NHS Maternity Statistics, England
2014-15), skin-to-skin contact after delivery, and exclusive breast-
milk feeding in the first weeks of life (NHS England Breastfeeding
Initiation Q1 2015/16), it is easy to understand how an infant’s
microbiome may be altered from its intended formation by the
absence of these events and the unintended gut colonisation of less
favourable bacteria from the hospital, staff, or feeding equipment.
It is thought that the altered microbiota may be responsible for
the colicky pain experienced by some infants and that prophy-
lactically receiving probiotics might protect the infant from that
colicky pain ever occurring, by steering the trajectory of microbial
gut colonisation nearer to that which was intended (Indrio 2014).
Of course, it is likely that there is no ’one cause’ of colic, and
potential multifactorial aetiologies may exist even in a single in-
fant with colicky symptoms, while certainly existing in the colicky
population.
Description of the intervention
The role of aberrant gut microbiota in infant colic has resulted
in the increased study of the use of probiotics in this area in re-
cent years (Braeggar 2011; Kukkonen 2008; Praveen 2014). Pro-
biotics are live organisms with potential health benefits; they pro-
vide resilience to bacterial insult and threat to the host (Rijkers
2011).Lactobacillus and Bifidobacterium species are the organisms
most commonly used as probiotics; associated terms include ’pre-
biotics’ and ’synbiotics’. Prebiotics are indigestible food ingredi-
ents that benefit the host by selectively stimulating the favourable
growth or activity, or both, of one or more indigenous probiotic
bacteria (Roberfroid 2007). Synbiotics are products containing
both probiotics and prebiotics and are often used.
There have been numerous studies around the effectiveness of sup-
plementing the already symptomatic infant’s diet with various pro-
biotics and synbiotics to reduce the symptoms of colic, but these
seem inconclusive when taken as a whole (Savino 2010b; Sung
2014; Szajewska 2013). However, evidence is building around the
effectiveness of prophylactically supplementing the newborn in-
fant with probiotics to prevent colic and other symptoms (Indrio
2014; Oozeer 2013). Additionally, evidence is accumulating on
the safety of such an intervention (Savino 2010b).
How the intervention might work
Given the growing evidence that the intestinal microbiota in col-
icky infants differ from those in healthy controls, it is proposed that
supplying probiotic bacteria can redress this balance and provide
a healthier intestinal microbiota landscape (Savino 2010a; Savino
2013a, Savino 2013b). As the evidence base suggests, common
factors impact this colonisation process, such as birth by caesarean
section (Grönlund 1999), and it is proposed that offering probi-
otics prophylactically to all as a form of primary prevention could
offer significant benefit to the population with minimal risk.
Why it is important to do this review
As previously stated in Praveen 2014 and above, infantile colic is
a common disorder with a stressful effect on both the infant and
parent/carer; however, the pathogenesis of colic is poorly under-
stood and involves a range of risk factors. Some of the most com-
monly prescribed treatments for infant colic have been found to
be nomore effective than placebo (Garrison 2000; Lucassen 2000;
Savino 2012). It has been increasingly thought that gutmicrobiota
play an important role in the pathogenesis of colic (Savino 2007b),
and probiotic supplementation has been suggested as a treatment
for colic symptoms in the infant, although observational studies
and clinical trials have provided mixed reports on whether this is
beneficial (Savino 2010a; Sung 2012; Sung 2014). Two Cochrane
Reviews are currently underway examining the effects of probi-
otics for infantile colic and pain-relieving agents for the condition
(Praveen 2014; Savino 2012, respectively).
Considering the impact of the condition and the increasing scope
of oral probiotics in the field of neonatology (necrotising en-
terocolitis) and paediatrics (allergic enteritis) (Baldassarre 2010;
Deshpande 2010; Deshpande 2011), as well as the relatively low
cost and easy availability of probiotics, we believe it is important
to evaluate the current evidence on probiotics as a prophylactic
therapy to prevent the onset of infant colic, in terms of both effec-
tiveness and safety, using the rigorous methodology of a Cochrane
Review.
Increasingly, work is being undertaken to assess and describe mi-
crobiota in the days, weeks, and months after the infant’s birth,
for example, de Weerth 2013 reports the evolution of changes in
microbiota that match the course of infant colic resolving over
three months. This illustrates why it may be more effective to give
probiotics prophylactically, early in life, to ’prevent’ colic rather
than using them to try to treat it after it has occurred.
New, large-scale studies have come to light in this area of postnatal
probiotics, including Indrio 2014, which enrolled 589 infants in
a multicentric study; Pärtty 2013 with almost 100 preterm partic-
ipants; and Kukkonen 2008, which included over 1000 infants.
It is thus timely to revisit this area and assess the potential use
of probiotics as a preventative measure for colic, which if proven
effective, could reduce or eliminate infant and parent/carer stress
in the early weeks and months of a baby’s life the world over.
O B J E C T I V E S
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1. To assess the effectiveness and safety of prophylactic
probiotics for preventing or reducing colic in infants.
2. To identify the likely effective probiotic strains for such an
approach.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs).
Types of participants
We will include newborn infants younger than one month of age
without a diagnosis of infantile colic at recruitment, as defined by
the study.
Types of interventions
Wewill include any probiotic, alone or in combination with a pre-
biotic (also known as synbiotics), versus no intervention, another
intervention(s), or placebo, where the focus of the study is the
effect of the intervention on infantile colic. We will not consider
studies in which probiotics are given to infants for other purposes
and in which colic or crying is not one of the main outcomes of
interest. While, ideally, we are looking for comparisons of probi-
otic intervention versus no intervention, and probiotic interven-
tion versus placebo, we will include studies comparing probiotic
intervention with other interventions for separate analysis. In such
a situation, we will only draw conclusions from these trials when
there is evidence of the effectiveness of each intervention from
other (’versus no treatment or placebo’) trials.
Types of outcome measures
For all proposed outcomes, we will use final outcomes from the
end of the trials, and we will record the timings of these outcomes
as they may guide the subgroup analysis.
Primary outcomes
1. Reduction in the duration of crying (post-treatment versus
baseline). Data may be continuous (for example, hours per day)
or dichotomous (for example, reduction under a predefined
threshold, as determined by the trial authors).
2. Adverse effects, including parental depression and mental
illness, choking, bacterial infection, or apparent life-threatening
events (dichotomous outcome).
Secondary outcomes
1. The number of responders in each group after treatment.
We will define responders as those who experienced a decrease in
the daily, average crying time of 50% from baseline
(dichotomous outcome).
2. Reduction in frequency of crying episodes per 24 hours,
where frequency is specified in the trials separately to the
duration of the infant’s crying (post-treatment versus baseline)
(dichotomous outcome).
3. Infant sleep duration per 24 hours at seven, 14, and 21 days
(post-treatment versus baseline) (continuous outcome) or where
it is not grouped in this way in the individual trials, using a time
window of between seven and 28 days.
Search methods for identification of studies
We will identify relevant trials by searching the sources described
below.
Electronic searches
Wewill search the following electronic databases and trial registers
from inception onwards.
1. Cochrane Central Register of Controlled Trials
(CENTRAL; current issue) in the Cochrane Library, which
includes the Cochrane Developmental, Psychosocial and
Learning Problems Specialised Register.
2. MEDLINE Ovid (from 1946).
3. MEDLINE In-Process & Other Non-Indexed Citations
OvidSP (current issue).
4. MEDLINE Epub Ahead of Print Ovid (current issue).
5. Embase Ovid (from 1980).
6. CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; from 1937).
7. PsycINFO Ovid (from 1967).
8. Science Citation Index Expanded Web of Science (SCI;
from 1970).
9. Social Sciences Citation Index Web of Science (SSCI; from
1970).
10. Conference Proceedings Citation Index - Science Web of
Science (CPCI-S; from 1990).
11. Conference Proceedings Citation Index - Social Science &
Humanities Web of Science (CPCI-SS&H; from 1990).
12. LILACS (Latin American and Caribbean Health Science
Information Database; lilacs.bvsalud.org/en; all available years).
13. Cochrane Database of Systematic Reviews (CDSR; current
issue) in the Cochrane Library.
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14. Database of Abstracts of Reviews of Effects (DARE; current
issue) in the Cochrane Library.
15. Epistemonikos (limited to systematic reviews;
www.epistemonikos.org; all available years).
16. WorldCat (limited to theses; www.worldcat.org; all
available years).
17. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov; all available years).
18. World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; apps.who.int/trialsearch; all
available years).
We will search MEDLINE using the search strategy in Appendix
2, which uses the sensitivity maximising version of the Cochrane
highly sensitive search strategy for identifying RCTs or quasi-
RCTs, as recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Lefebvre 2011). We will adapt this strat-
egy for other databases, without imposing any date or language
restrictions. We will ensure the professional translation in full of
studies published in languages other than English.
Searching other resources
Grey literature
We will handsearch abstracts presented at relevant international
meetings, including the European Society for Paediatric Gastroen-
terologyHaematology andNutrition (ESPGHAN) and theNorth
American Society for Pediatric Gastroenterology, Hepatology and
Nutrition (NASPGHAN), published from their earliest availabil-
ity (2010) until the most recent meeting (2015), with the aim of
finding relevant studies that are not yet published in full. There is
some evidence that data from abstracts can be inconsistent with
data in published articles (Pitkin 1999). Therefore, wewill only in-
clude abstract publications if they present sufficient data on which
to judge inclusion and assess quality. Where they do not present
such data, wewill attempt to contact authors formore information
and meanwhile list them under ’Studies awaiting classification’.
Supplementary searching
We will inspect the references of all relevant studies and reviews
and contact authors to request missing or incomplete data. In
addition, we will run citation searches of included studies.
Personal contacts
Wewill contact leaders in the field to try to identify other published
and unpublished studies.
Pharmaceutical companies
Wewill contact companies that produce probiotics and synbiotics,
as well as companies that produce medication and formula prepa-
rations, as per the Background section, to search for any other
relevant ongoing and unpublished studies.
Data collection and analysis
Selection of studies
Having collated references and removed duplicates, two reviewers
(MG and SSCB) will independently screen titles, abstracts, and
full reports for eligibility against the inclusion criteria (see Criteria
for considering studies for this review). Specifically, they will un-
dertake the following tasks:
1. merge search results using reference management software
and remove duplicate records of the same report;
2. examine titles then abstracts, and remove any records that
do not meet the inclusion criteria;
3. retrieve the full texts of potentially relevant reports;
4. link together multiple reports of the same study;
5. examine full-text reports to determine whether studies meet
the eligibility criteria;
6. correspond with investigators, when appropriate, to clarify
study eligibility;
7. at all stages, note reasons for inclusion and exclusion of
articles on a study flow spreadsheet, and resolve any
disagreements through consensus;
8. make final decisions on study inclusion and resolve any
discrepancies through a process of consensus; and
9. proceed to data collection.
Wewill record our selection process in a PRISMAdiagram (Moher
2009).
Data extraction and management
We will develop data extraction forms a priori, as per the recom-
mendations in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a). We will extract the following in-
formation.
1. Characteristics of participants: source of participants,
inclusion and exclusion criteria, total number at baseline, total
number at completion, setting, definition of ’colic’ applied,
diagnostic criteria applied, type of feeding (breastfeeding,
formula feeding), age at onset of colic, age at commencement of
intervention, and evaluation of potential effect modifiers (e.g.
age, gender).
2. Interventions and controls: number of groups,
intervention(s) applied, frequency and duration of treatment,
total number of treatments, and permitted cointerventions.
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3. Methods: study design and duration, sequence generation,
allocation concealment, blinding of outcome assessors, and
evaluation of success of blinding.
4. Outcomes: outcomes assessed, definitions used, values of
means and standard deviations (SDs) at baseline and at time
points as defined by the study protocol (or change from baseline
measures, if given).
5. Results: measures at the end of the protocol, follow-up data
(including means and SDs, standard errors, or confidence
intervals (CI) for continuous data, and summary tables for
dichotomous data), withdrawals, and losses to follow-up.
6. Other: references to other relevant studies, points to follow-
up with the study authors, comments from the study authors,
key conclusions from the study (by the study authors), and other
comments from the review authors.
Two review authors (MG and SSCB) will extract the data inde-
pendently using the data extraction form. A third review author
(MRT) will resolve any disagreements. We will collate data in the
latest version of Review Manager (RevMan 2014).
Assessment of risk of bias in included studies
Two review authors (MG and SSCB) will independently evaluate
each study for risk of bias using the criteria recommended in the
Cochrane Handbook for Systematic Reviews of Interventions for the
following domains (Deeks 2011;Higgins 2011b): sequence gener-
ation; allocation concealment; blinding of parents and health pro-
fessionals; blinding of outcome assessment; incomplete outcome
data; selective outcome reporting; and other potential threats to
validity. We will judge each domain as being at ’low’, ’high’, or
’unclear’ risk of bias. We will compare the judgments and discuss
and resolve any inconsistencies in the assessments. A third review
author (MRT) will resolve any persisting disagreements.
Sequence generation for randomisation
We will include only RCTs in the review. We will assess randomi-
sation as being at low risk of bias if the procedure of randomi-
sation sequence generation was explicitly described; examples in-
clude computer-generated random numbers, a random numbers
table, or coin-tossing. If no description is given, we will contact
the authors for further information, and if we fail to receive a
response, we will assign a judgment of unclear risk of bias. We
will consider studies that use non-randomised procedures (hospi-
tal number, date of birth) to have a high risk of bias.
Allocation concealment
We will assess concealment of treatment allocation as being at low
risk of bias if the procedure was explicitly described and adequate
efforts weremade to ensure that intervention allocations could not
have been foreseen in advance of, or during, enrolment; examples
include centralised randomisation, numbered or coded containers,
or sealed envelopes. Procedures that we will consider to have a high
risk of bias include alternation or reference to case record numbers
or dates of birth. We will also assign a judgement of high risk of
bias to studies in which allocation concealment did not occur as
intervention allocation may not have been in a random fashion
and may have increased bias. We will contact the study authors
if no description is given, and if we do not receive a response, we
will assign a judgment of unclear risk of bias.
Blinding of parents and health professionals
In this context, the intervention is administered by parents, so in
effect, we will consider them the target of the blinding procedures.
Indeed, as the participants will be less than four months of age
by the defined inclusion criteria, it is deemed that this item is not
applicable to them. Furthermore, parents often act as outcome
assessors. We will primarily assess the risk of bias associated with
the blinding of parents of participants based on the likelihood
that such blinding was sufficient to ensure that parents had no
knowledge of which intervention the infant received.
Blinding of outcome assessment
For each included study, we will describe the methods used, if
any, to blind the outcome assessors from knowledge of which
intervention a participant received. We will judge studies to be
at low risk of bias if they blinded the outcome assessors, or if
we consider that the lack of blinding could not have affected the
results. If blinding was not done or was not possible because of
the nature of the intervention, we will judge the study to be at
high risk of bias because it is possible that the lack of blinding
influenced the results. If no description is given, we will contact
the study authors for more information, and if we do not receive
a response, we will assign a judgment of unclear risk of bias. We
will note the blinding of health professionals if reported.
Incomplete outcome data
Incomplete outcome data essentially include attrition, exclusions,
and missing data.
We will assign a judgment of low risk of bias in the following
instances:
1. if participants included in the analysis are exactly those who
were randomised into the trial; missing outcome data are
balanced in terms of numbers across intervention groups, with
similar reasons for missing data across groups; or if there are no
missing outcome data;
2. if for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk is not sufficient to
have a clinically relevant impact on the intervention effect
estimate;
3. if for continuous outcome data, the plausible effect size
(standardised mean difference (SMD)) among missing outcomes
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is not sufficient to have a clinically relevant impact on observed
effect size; or
4. if missing data have been imputed using appropriate
methods.
We will assign a judgment of high risk of bias in the following
instances:
1. when reasons for missing outcome data are likely to be
related to the true outcome, with either an imbalance in
numbers or reasons for missing data across intervention groups;
2. when for dichotomous outcome data, the proportion of
missing outcomes compared with the observed event risk is
sufficient to induce clinically relevant bias in the intervention
effect estimate;
3. when for continuous outcome data, the plausible effect size
(SMD) among missing outcomes is sufficient to induce clinically
relevant bias in the observed effect size;
4. when an ’as-treated’ analysis is carried out in cases where
there is a substantial departure of the intervention received from
that assigned at randomisation; or
5. when there is a potentially inappropriate application of
simple imputation.
We will assign a judgment of unclear risk of bias in the following
instances:
1. when there is insufficient reporting of attrition or
exclusions, or both, to permit a judgment of low or high risk of
bias;
2. when the study reported incomplete outcome data; or
3. when the trial did not clearly report the numbers
randomised to intervention and control groups.
Selective outcome reporting
We will assess the reporting of outcomes as being at low risk of
bias if the results of the trial report all of the study outcomes de-
clared in the trial’s methods section. We will also evaluate whether
different reports of the study are available, including protocols,
and examine them to ensure that there is no suggestion of selective
outcome reporting. If no description is given, we will contact the
authors for more information, and if we do not receive a response,
we will assign a judgment of unclear risk of bias. If there is evi-
dence of selective reporting (deviation from protocol, key planned
outcomes not reported), we will assign a judgment of high risk of
bias.
Other potential threats to validity
If the study is at risk of other sources of bias not captured by the
above domains, we will assess it as being at high risk of bias, for
instance, if the study was stopped early due to a data-dependent
process, having a baseline imbalance between the group, or its
sources of sponsorship or funding.Wewill assess the study as being
at low risk of bias if it appears to be free from such threats to validity.
When the risk of bias is unclear from the published information,
we will attempt to contact the study authors for clarification. If
this is not forthcoming, we will assess these studies as being at
unclear risk of bias.
Measures of treatment effect
Dichotomous data
We will present dichotomous data as risk ratios (RR), since the
effects of the RR are readily understood (Walter 2000). We will
report all RRs with their associated 95% confidence intervals (CIs)
and probability values (when possible).
Continuous data
If all studies use the same measurement scale, we will calculate
mean differences (MD). When studies use different scales, we will
calculate the SMD using Hedges’ g. We will also report the 95%
CI of the MD or SMD.
If necessary, we will calculate effect estimates from P values, t-
statistics, analysis of variance (ANOVA) tables, or other statistics,
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Deeks 2011), but only in situations when the
raw data (MD or SMD) are not directly available in the study
publications.
For this analysis, we will use, according to need, either change
scores or final values without combining them.
If both continuous and dichotomous data are available for an out-
come, we will include only the continuous outcome in the primary
analysis. If some studies report an outcome as a dichotomous mea-
sure and others use a continuous measure of the same construct,
we will convert the results for the former from the dichotomous
measure to a SMD, provided that we can assume that the underly-
ing continuous measure has approximately a normal or logistical
distribution. (Otherwise, we will carry out two separate analyses.)
Unit of analysis issues
Cluster-randomised studies
For each included study, we will determine whether the unit of
analysis is appropriate for the unit of randomisation and the design
of that study (that is, whether the number of observations matches
the number of randomised ’units’ (Deeks 2011)). It is unlikely
that we will find cluster-randomised trials because such a design is
uncommon in this field. However, if we do, we will use the intra-
class correlation coefficient (ICC) to convert trials to their effective
sample size before incorporating them into the meta-analysis, as
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011b). If the ICC is not available, we will
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use values from the published literature as an external source, when
available, as well as contacting the study author to supply more
data to allow calculation of an ICC estimate (Campbell 2000). It
is only for those cluster trials that did not account for the cluster
effects that we will use the ICC to calculate the effective sample
size or the effective SD.
Studies with multiple treatment arms
In the primary analysis, we will combine results across all eligi-
ble intervention arms and compare them with the combined re-
sults across all eligible control arms (another intervention(s) or
placebo), making single pairwise comparisons. Where such a strat-
egy prevents investigation of potential sources of heterogeneity, we
will analyse each type separately (against a common control group:
placebo), but divide the sample size for common comparator arms
proportionately across each comparison (Higgins 2011b). This
simple approach allows the use of standard software (including
RevMan 2014) and prevents the inappropriate double-counting
of individuals.
Cross-over studies
In randomised, cross-over studies, individuals receive each inter-
vention sequentially, in a random order. Cross-over studies usually
contain a washout period, which is a stage after the first treatment
but before the second treatment, where time is given for the active
effects of the first treatment to wear off before the new treatment
begins (that is, to reduce the carry-over effect). A concern with the
cross-over design is the risk of a carry-over effect (when the first
treatment affects the second), which is of particular concern for
this review given the nature of the interventions we are assessing.
For this review, we will not include any data in cross-over studies
after the first treatment period.
Dealing with missing data
Where data are missing, we will contact the corresponding authors
of included studies to supply any unreported data.
For all outcomes in all studies, we will carry out analyses as far as
possible on an intention-to-treat basis; that is, we will attempt to
include all participants randomised to each group in the analyses,
and we will analyse all participants in the group to which theywere
allocated regardless of whether or not they received the allocated
intervention.
For missing continuous data, we will estimate SDs from other
available data, such as standard errors, or we will impute them
using the methods suggested in Higgins 2011b. We will conduct
analyses based on participants completing the trial, in line with
available case analysis; this will assume that missing data are at
random. If there is a discrepancy between the number randomised
and the number analysed in each treatment group,wewill calculate
and report the percentage lost to follow-up in each group.
When it is not possible to obtain missing data, we will record this
in the data collection form, report it in the ’Risk of bias’ table, and
discuss the extent to which the missing data could alter the results
and hence the conclusions of the review. For included studies, we
will note levels of attrition.Wewill explore the impact of including
studies with high levels of missing data in the overall assessment of
treatment effect by conducting sensitivity analyses (see Sensitivity
analysis).
Assessment of heterogeneity
We will assess clinical heterogeneity by comparing the distribu-
tion of important participant characteristics between trials (for ex-
ample, age) and trial characteristics (for example, randomisation,
concealment, blinding of outcome assessment, losses to follow-
up, treatment type, cointerventions).
We will employ a Chi² test of homogeneity, with a 10% level of
significance, to determine the strength of evidence that hetero-
geneity is genuine. We will also present tau².
In addition, we will assess statistical heterogeneity by examining
the I² statistic (Deeks 2011), a quantity that describes the propor-
tion of variation in point estimates that is due to variability across
studies rather than sampling error.We will interpret the I² statistic
as suggested in the latest version of Deeks 2011:
1. 0% to 40%: might not be important;
2. 30% to 60%: may represent moderate heterogeneity;
3. 50% to 90%: may represent substantial heterogeneity; and
4. 75% to 100%: suggests considerable heterogeneity.
Assessment of reporting biases
In order to minimise publication bias, we will attempt to obtain
the results of any unpublished studies, in order to compare the
results extracted from published journal reports with the results
obtained from other sources (including correspondences).
In addition, if there are more than 10 studies grouped in a com-
parison, we will evaluate whether reporting biases are present by
using funnel plots to investigate any relationship between effect
estimates and study size or precision, or both, as recommended
in the Cochrane Handbook for Systematic Reviews of Interventions
(Sterne 2011). Due to the small number of studies expected, no
formal test for plot asymmetry is planned.
Data synthesis
When interventions are similar in terms of type of intervention,
type of outcome assessed, and type of colic, we plan to group
the studies and synthesise their results in a meta-analysis. We will
present results for each combination of probiotic intervention, as-
sessed outcome, and colic type, with the exception of those studies
for which no data are observed. For instance, if two or more stud-
ies assessed the effects of prophylactic probiotic use in otherwise
healthy children with colic and both measured daily crying, we
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will perform a meta-analysis of the results. Because we assume that
clinical heterogeneity is very likely to impact on our review results,
given the wide breadth and types of interventions included, we
will combine the studies using a random-effects model, regardless
of statistical evidence of heterogeneity of effect sizes, calculating
individual treatment effects and assigning weight using inverse
variance. We will use these calculations to produce a pooled effect,
which we will present in a forest plot. We will carry out statistical
analysis using RevMan 2014. When data are insufficient, we will
provide a narrative description of the results.
’Summary of findings’ tables
We will assess the overall quality of evidence using the GRADE
approach (Guyatt 2008). The GRADE approach appraises the
quality of a body of evidence based on the extent to which one
can be confident that an estimate of effect, or association, reflects
the item being assessed. RCTs start as high-quality evidence, but
may be downgraded due to risk of bias (methodological quality),
indirectness of evidence, unexplained heterogeneity, imprecision
(sparse data), and publication bias. Two review authors (SB and
MG) will independently assess the overall quality of the evidence
for each outcome after considering each of these factors and will
grade them as follows:
1. high quality: further research is very unlikely to change
confidence in the estimate of effect;
2. moderate quality: further research is likely to have an
important impact on confidence in the estimate of effect, and
may change the estimate;
3. low quality: further research is very likely to have an
important impact on confidence in the estimate of effect, and is
likely to change the estimate; or
4. very low quality: any estimate of effect is very uncertain.
We will use the outcomes below.
1. A reduction in the duration of crying (post-treatment
versus baseline).
2. Adverse effects, including parental depression and mental
illness, choking, bacterial infection, or apparent life-threatening
events.
3. The number of responders in each group after treatment.
We will define responders as those who experienced a decrease in
the daily, average crying time such that they would no longer be
defined as having infantile colic.
4. Reduction in frequency of crying episodes per 24 hours,
where frequency is specified in the trials separately to the
duration of the infant’s crying (post-treatment versus baseline).
5. Infant sleep duration per 24 hours at seven, 14, and 21 days
(post-treatment versus baseline) or where it is not grouped in this
way in the individual trials, using a time window of between
seven and 28 days.
Subgroup analysis and investigation of heterogeneity
Large numbers of subgroup analyses may lead to misleading con-
clusions (Oxman 1992; Yusuf 1991). We plan to carry out the
following subgroup analyses, when possible:
1. mode of delivery of baby (vaginal versus caesarean section);
2. type of feeding (artificially fed versus breastfed);
3. short-term and long-term follow-up (fewer than four weeks
versus four weeks or more of treatment);
4. preterm (pre-37 weeks and pre-33 weeks gestation) versus
’term’ babies (born between 37 and 43 weeks gestation);
5. low-quality trials versus high-quality trials (allocation
concealment versus lack of allocation concealment; blinding
versus lack of blinding); and
6. type of probiotic (or combination of probiotic with
prebiotic, also known as ’synbiotic’).
These analyses will be exploratory as they involve non-experimen-
tal (cross study) comparisons and will involve primary outcomes.
We will treat any conclusions with caution.
Sensitivity analysis
Wewill conduct sensitivity analyses to determine whether findings
are sensitive to the following:
1. bias, by restricting the analyses to studies judged to be at
low risk of bias for blinded assessment of the primary outcome;
2. imputed data, by calculating the treatment effect including
and excluding the imputed data to assess whether this alters the
outcome of the analysis;
3. dropouts and exclusions, by conducting worst-case versus
best-case scenario analyses;
4. the definition of colic used, by conducting analyses on
studies using the stringent Wessel definition of infant colic
(Wessel 1954), the more recent definition given by Hyman
2006, and a non-recognised definition; and
5. the choice of meta-analysis model used, by comparing
results from the fixed-effect model with those of the random-
effects model.
While there may be heterogeneity in the interventions, as well as
the comparisons, we consider that the consensus on definitions of
symptoms for eligibility manages the risk of ’blurring’ the results,
but we remain vigilant, and if we perceive a risk while evaluating
our findings, we may undertake a sensitivity analysis removing
such trials to provide more definite findings.
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Term Definition
Paroxysms A sudden recurrence or intensification of symptoms such as a spasm or seizure. Also called paroxysmal
attacks
Dysmotility A condition in which muscles of the digestive system become impaired and changes in the speed, strength
or coordination in the digestive organs occurs. In the normal small intestine, liquefied food and secretions,
including digestive enzymes are pushed onwards by waves of muscular contraction
Oligosaccharides A saccharide polymer (complex carbohydrate) containing a small number of simple sugars, which are not
digestible by humans, and instead function as prebiotics to support the growth of certain types of bacteria
in the gut
Microbiota “the ecological community of commensal, symbiotic and pathogenic microorganisms that literally share
our body space.” (Lederberg 2001)
Microbiome The microorganisms in a particular environment (including the body or a part of the body)
Coliforms Coliform bacteria are an indicator of sanitary quality of foods and water. They ferment lactose with the
production of acid and gas. Coliforms can be found in the aquatic environment, in soil and on vegetation;
they are universally present in large numbers in the faeces of warm-blooded animals. While coliforms
themselves are not normally causes of serious illness, they are easy to culture, and their presence is used
to indicate that other pathogenic organisms of faecal origin may be present. Such pathogens include
disease-causing bacteria, viruses, or protozoa and many multicellular parasites. Coliform procedures may
be performed in aerobic or anaerobic conditions
Necrotising enterocolitis A medical condition primarily seen in premature infants where portions of the bowel undergo necrosis
(tissue death). It occurs postnatally and is one of the most common causes of morbidity in premature
infants
Enteritis Inflammation of the intestine, especially the small intestine, usually accompanied by diarrhoea
Appendix 2. MEDLINE search strategy
1 colic/
2 colic$.tw.
3 ((stomach or abdominal or abdomen$) adj3 (spasm$ or pain$ or cramp$)).tw.
4 ((gastric or gastro$) adj3 (spasm$ or pain$ or cramp$)).tw.
5 crying/
6 (cry or crying or cries).tw.
7 or/1-6
8 Dietary Supplements/
9 Complementary Therapies/
10 Gastrointestinal Agents/
11 probiotics/
12 (probiotic$ or synbiotic$).mp.
13 exp lactobacillaceae/
14 lactobac?ill$.mp.
15 exp Bifidobacterium/
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16 Bifidobacter$.mp.
17 Bifidus$.mp.
18 exp Saccharomyces/
19 Saccharomyces$.mp.
20 Streptococcus/
21 streptococc$.mp.
22 (Biogaia or Culturelle or Enflora$ or Florastor or ((Gerber$ or Nestle$) adj2 (Goodstart or Good Start)) or Nutramigen or VSL?
3).tw.
23 or/8-22
24 exp infant/
25 (baby or babies or infant$ or child$ or newborn$ or neonat$).tw.
26 24 or 25
27 randomised controlled trial.pt.
28 controlled clinical trial.pt.
29 randomi#ed.ab.
30 placebo$.ab.
31 drug therapy.fs.
32 randomly.ab.
33 trial.ab.
34 groups.ab.
35 or/27-34
36 exp animals/ not humans.sh.
37 35 not 36
38 7 and 23 and 26 and 37
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